Comparison between a new platelet count drop method PL-11, light transmission aggregometry,VerifyNow aspirin system and thromboelastography for monitoring short-term aspirin effects in healthy individuals

Platelet function has been described by many laboratory assays, and PL-11 is a new point-of-care platelet function analyzer based on platelet count drop method, which counts platelet before and after the addition of agonists in the citrated whole blood samples. The present study sought to compare PL-11 with other three major more established assays, light transmission aggregometry (LTA), VerifyNow? aspirin system and thromboelastography (TEG), for monitoring the short-term aspirin responses in healthy individuals. Ten healthy young men took 100?mg/d aspirin for 3-day treatment. Platelet function was measured via PL-11, LTA, VerifyNow and TEG, respectively. The blood samples were collected at baseline, 2 hour, 1 day during the aspirin treatment and 1 day, 5?±?1 days, 8?±?1 days after the aspirin withdrawal. Moreover, 90 additional healthy subjects were recruited to establish a reference range for PL-11. Platelet function of healthy subjects decreased significantly 2 hours after 100?mg/d aspirin intake and began to recover during 4–6 days after the aspirin withdrawal. Correlations between methods were PL-11 vs. LTA (r?=?0.614, p?<?0.01); PL-11 vs. VerifyNow (r?=?0.829, p?<?0.01); PL-11 vs. TEG (r?=?0.697, p?<?0.001). There was no significant bias between PL-11 and LTA at baseline (bias?=?1.94%, p?=?0.804) using Bland-Altman analysis, while the data of PL-11 were significantly higher than LTA (bias?=?24.02%, p?<?0.001) during the aspirin therapy. The reference range for PL-11 in healthy young individuals was from 66.8 to 90.5% (95%CI). When aspirin low-responsiveness was defined as LTA?>?20%, the cut-off values for each method were, respectively: PL-11?>?50%, VerifyNow?>?533 ARU, TEG?>?60.2%. The results of different platelet function assays were uninterchangeable for monitoring aspirin response and correlations among them were also varied. Correlations among PL-11 and other three major assays suggested the ability of PL-11 to assess the treatment effects of aspirin. But a large cohort study is needed to confirm the cut-off value of aspirin response detected by PL-11.     

逍遥丸对皮质酮诱导小鼠抑郁样行为的干预机制※

目的:观察逍遥丸对皮质酮诱导小鼠抑郁样行为的干预作用,并探讨其分子机制。方法:将50只ICR雄性小鼠,随机分为5组:正常组、皮质酮模型组、阳性对照氟西汀组(20 mg/kg)、低剂量逍遥丸(200 mg/kg)组、高剂量逍遥丸组(600 mg/kg),通过皮下注射皮质酮诱导小鼠抑郁模型。持续35天后,采用糖水偏好实验和强迫游泳实验评价动物抑郁样行为;采用ELISA方法测小鼠血清中皮质酮含量及小鼠海马组织中脑源性神经营养因子(BDNF)的含量。结果:皮质酮可以降低糖水偏好值、增加小鼠强迫游泳的不动时间,而逍遥丸可以显著提高糖水偏好值、减少小鼠不动时间;长期注射皮质酮可增加血清皮质酮水平,降低海马组织中BDNF含量,而逍遥丸可以降低小鼠血清中皮质酮的含量并且能够提高海马组织中BDNF含量。结论:逍遥丸可以有效降低小鼠血清中皮质酮的含量并增加小鼠海马中BDNF含量,改善神经营养系统,产生抗抑郁样作用。     

金珠滴眼液治疗慢性结膜炎的临床研究

目的　探讨金珠滴眼液治疗慢性结膜炎的疗效。方法　将慢性结膜炎患者 36例 6 8眼随机分为2组 ,每组 34眼 ,实验组用 7.8%金珠滴眼液点眼治疗 ,对照组用 0 .2 5 %氯霉素点眼治疗。结果　金珠滴眼液1、2、4周疗效的综合分值判定均与对照组有显著差异 (P <0 .0 5 ) ,且无局部刺激性。结论　金珠滴眼液对慢性结膜炎有明显的治疗作用 ,可望为临床常见多发的慢性结膜炎患者消除或缓解症状     

清宫止血颗粒防治药流后阴道出血的临床观察附:178例病例报告

目的：探寻防治药流后阴道不规则出血的有效、低毒新药，为进一步推广此法扫清障碍。方法：将符合诊断和入选标准的药流后阴道不规则出血、并自愿参予本课题临床试验的178例受试者分为3组，即：清宫止血颗粒治疗组(66例)、益母草对照组(59例)和空白对照组(53例)，在严密观察和保证安全的前提下进行试验。前2组在接受药流后分别服用清宫止血颗粒、益母草冲剂治疗，空白对照组则不服用任何药物，观察其自然恢复过程。结果：清宫颗粒组受试者其出血时间短于其余2组(P＜0．0l或P＜0．05)；其出血量少于其余2组(P＜0．0l或P＜0．05)；其完全流产率高于其余2组(P＜0．0l或P＜0．05)；其月经恢复时间短于其余2组(P＜0．0l或P＜0．05)。结论：清宫止血颗粒对药流后不规则阴道出血有良好的防治作用，其疗效优于益母草冲剂。     

一种有效提高小丸微波干燥能力及质量的装置

介绍一种能提高小丸微波干燥能力,避免小丸干燥开裂、过火等现象,可以提高小丸微波干燥均匀度的装置。